Differences among hemoglobin thresholds for red blood cell transfusions in patients with hematological diseases in teaching hospitals: a real world data in Japan

International Journal of Hematology
Akihiko YokohamaKazuo Muroi

Abstract

A hemoglobin (Hb) threshold level of 7 g/dL has been proposed for red blood cell (RBC) transfusion in patients with chronic anemia in the Japanese guideline since 2005. However, Hb thresholds for hematological diseases in clinical practice and factors responsible for higher Hb thresholds remain unclear. Hb thresholds were collected for patients with hematological diseases from 32 Japanese teaching hospitals. Uni- and multivariate analyses were used to analyze relationships between Hb threshold level and various patient and hospital factors. In total, 4996 units of RBC were transfused to 1054 patients with hematological diseases in 2421 transfusions. Median age was 68 years. Myelodysplastic syndrome was the most frequent diagnosis. Overall median Hb threshold level was 6.9 g/dL. Multivariate linear regression analysis detected the following variables associated with Hb threshold level: hospital; cardiovascular disease; symptomatic anemia; and hematopoietic stem cell transplantation. Hospital was the most significant factor. Collectively, median Hb threshold level in clinical practice in Japan was similar to the guidelines. Higher Hb threshold level depended on the hospitals at which the transfusions were performed as well as pat...Continue Reading

References

Apr 20, 2007·The New England Journal of Medicine·Jacques LacroixUNKNOWN Pediatric Acute Lung Injury and Sepsis Investigators Network
Oct 14, 2010·JAMA : the Journal of the American Medical Association·Ludhmila A HajjarJose O C Auler
Jul 28, 2011·The American Journal of Cardiology·Howard A CooperJulio A Panza
Nov 22, 2011·Transfusion·Mark H Yazer, Jonathan H Waters
Dec 16, 2011·The New England Journal of Medicine·Jeffrey L CarsonUNKNOWN FOCUS Investigators
Nov 10, 2012·Journal of Pediatric Hematology/oncology·Rachel S Bercovitz, Ralph R Quinones
Jan 4, 2013·The New England Journal of Medicine·Càndid VillanuevaCarlos Guarner
Apr 30, 2013·Transfusion·Steven M FrankPaul M Ness
Oct 2, 2014·The New England Journal of Medicine·Lars B HolstUNKNOWN Scandinavian Critical Care Trials Group
Nov 18, 2014·Anesthesiology·Juliano Pinheiro de AlmeidaLudhmila Abrahao Hajjar
Mar 12, 2015·The New England Journal of Medicine·Gavin J MurphyUNKNOWN TITRe2 Investigators
Nov 17, 2015·British Journal of Haematology·Sally B KillickUNKNOWN British Society for Standards in Haematology
Oct 13, 2016·JAMA : the Journal of the American Medical Association·Jeffrey L CarsonAaron A R Tobian
Feb 23, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M AaproUNKNOWN ESMO Guidelines Committee
Oct 1, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M AaproUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

❮ Previous
Next ❯

Citations

Jun 4, 2021·International Journal of Hematology·Akiyoshi TakamiUNKNOWN Japanese Society for Laboratory Hematology Standardization Committee (JSLH-SC) and Joint Working Group of the JSLH and the J

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.